Cargando…
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...
Autores principales: | Gunerka, Paweł, Gala, Kamila, Banach, Martyna, Dominowski, Jakub, Hucz-Kalitowska, Joanna, Mulewski, Krzysztof, Hajnal, Agnes, Mikus, Endre G., Smuga, Damian, Zagozda, Marcin, Dubiel, Krzysztof, Pieczykolan, Jerzy, Zygmunt, Beata M., Wieczorek, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377474/ https://www.ncbi.nlm.nih.gov/pubmed/32702053 http://dx.doi.org/10.1371/journal.pone.0236159 |
Ejemplares similares
-
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives
por: Stypik, Mariola, et al.
Publicado: (2022) -
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives
por: Stypik, Mariola, et al.
Publicado: (2022) -
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
por: Matloka, Mikolaj, et al.
Publicado: (2022) -
The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415)
por: Michałek, Stanisław, et al.
Publicado: (2022) -
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
por: Bazydlo-Guzenda, Katarzyna, et al.
Publicado: (2021)